<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003210</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02264</org_study_id>
    <secondary_id>NCI-2012-02264</secondary_id>
    <secondary_id>CDR0000066067</secondary_id>
    <secondary_id>NCI-T97-0050</secondary_id>
    <secondary_id>DM-97073</secondary_id>
    <secondary_id>T97-0050</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <nct_id>NCT00003210</nct_id>
  </id_info>
  <brief_title>Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease</brief_title>
  <official_title>A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of interleukin-12 in treating patients with&#xD;
      previously treated non-Hodgkin's lymphoma or Hodgkin's disease. Interleukin-12 may kill tumor&#xD;
      cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to&#xD;
      kill lymphoma cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate of interleukin-12 in previously treated patients with&#xD;
      non-Hodgkin's lymphoma or Hodgkin's disease.&#xD;
&#xD;
      II. To determine the in vivo regulatory effect of interleukin-12 on Fas lingand (FasL)&#xD;
      expression on patients' peripheral blood lymphocytes.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease characteristics: low grade&#xD;
      non-Hodgkin's lymphoma (follicular small cleaved, follicular mixed, small lymphocytic, and&#xD;
      variants) versus intermediate grade non-Hodgkin's lymphoma (follicular large, diffuse large,&#xD;
      diffuse mixed, immunoblastic, peripheral T-cell, and mantle cell) versus Hodgkin's disease.&#xD;
&#xD;
      Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36-105 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Simon's two-stage model will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC version 2.0</measure>
    <time_frame>Up to 5 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (interleukin-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment (interleukin-12)</arm_group_label>
    <other_name>cytotoxic lymphocyte maturation factor</other_name>
    <other_name>IL-12</other_name>
    <other_name>interleukin-12</other_name>
    <other_name>natural killer cell stimulatory factor</other_name>
    <other_name>Ro 24-7472</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (interleukin-12)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously treated non-Hodgkin's lymphoma (all histologies except lymphoblastic and&#xD;
             Burkitt's lymphoma) or Hodgkin's disease&#xD;
&#xD;
          -  Maximum of 4 previous treatment regimens&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  Performance status - Karnofsky 80-100%&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1500/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT less than 2 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No severe cardiovascular disease including active ischemic heart disease, congestive&#xD;
             heart failure, or major arrhythmias&#xD;
&#xD;
          -  No severe pulmonary disease including dyspnea with moderate to severe exertion&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use adequate contraception&#xD;
&#xD;
          -  No clinically significant autoimmune disease (e.g. rheumatoid arthritis)&#xD;
&#xD;
          -  No clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer&#xD;
&#xD;
          -  No prior allogeneic bone marrow or stem cell transplant&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy for lymphoma&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for lymphoma&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy for lymphoma&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for lymphoma&#xD;
&#xD;
          -  At least 2 weeks since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2003</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

